Carbamazepine‑10,11 Epoxide, Serum/Plasma
Use
Monitoring of carbamazepine’s active metabolite, carbamazepine‑10,11‑epoxide, aids therapeutic drug management, particularly when co‑medications may alter metabolism; helps assess seizure control and risk of toxicity.
Special Instructions
Not provided.
Limitations
Not cleared or approved by the U.S. Food and Drug Administration; analytical performance validated under CLIA regulations. Results may be influenced by specimen type; serum separator (gel) tubes are not acceptable and may cause falsely low levels due to drug absorption into the gel. Specimen must be separated promptly after collection.
Methodology
Mass Spectrometry
Biomarkers
Carbamazepine‑10,11 Epoxide
Analyte
Result Turnaround Time
2 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
2 mL
Minimum Volume
1 mL
Container
Red‑top tube (no gel)
Collection Instructions
Centrifuge and immediately separate serum from cells into clean plastic screw‑capped vial
Causes for Rejection
Serum separator tube (SST®)
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 14 days |
| Refrigerated | 14 days |
| Frozen | 10 months |
Other tests from different labs that may be relevant